Research Article
Efficacy Analysis of Combining Sintilimab with Neoadjuvant Chemotherapy in Treating Middle and Advanced Rectal Cancer Based on Big Data
Table 3
Analysis of factors related to treatment effectiveness.
| | Related factors | Ineffective group () | Effective group () | | |
| | Age (>55 years) | 10 (72.92) | 13 (43.33) | 4.113 | 0.043 | | Gender (male) | 7 (53.85) | 21 (70.00) | 1.042 | 0.307 | | Tumor size (≥3 cm) | 8 (61.54) | 8 (26.67) | 4.721 | 0.030 | | Distance between tumor and anal verge (≥5 cm) | 7 (53.85) | 16 (53.33) | 1.042 | 0.307 | | Concurrent chemotherapy cycle (≥3 weeks) | 6 (46.15) | 11 (36.67) | 0.342 | 0.559 | | Neoadjuvant chemotherapy cycle (≥2 weeks) | 8 (61.54) | 16 (53.33) | 0.248 | 0.619 | | White blood cell count (×109/L) | | | 0.981 | 0.332 | | Neutrophil (×109/L) | | | 0.175 | 0.862 | | Lymphocyte (×109/L) | | | 0.119 | 0.906 | | Platelet (×109/L) | | | 0.063 | 0.950 | | CEA (ng/mL) | | | 5.836 | <0.001 | | CA199 (IU/mL) | | | 1.575 | 0.123 | | NLR value | | | 2.098 | 0.042 | | PLR value | | | 3.044 | 0.004 | | TNM stage | | | 4.488 | 0.034 | | IIc | 1 (7.69) | 12 (40.00) | | | | III | 12 (92.31) | 18 (60.00) | | | | Lymphatic metastasis | 12 (92.31) | 18 (60.00) | 4.488 | 0.034 |
|
|
